University of Birmingham’s Precision Health Technologies Accelerator (PHTA) to lead UK in next-generation medicine manufacturing with major Government investment

Birmingham is set to become a national hub for the manufacturing of next-generation medicines, following a major new investment from the UK Government into advanced therapeutics, vaccines, and clinical trial capability.

The Government has announced multi-million-pound funding through the Life Sciences Innovative Manufacturing Fund (LSIMF) to support the development of three Good Manufacturing Practice (GMP) standard cleanrooms at the University of Birmingham’s Precision Health Technologies Accelerator (PHTA).

These will enable the production of Advanced Therapy Medicinal Products (ATMPs), including cell and gene therapies and mRNA vaccines, for both clinical trials and direct patient treatment.

The Government’s investment into the University of Birmingham’s PHTA will contribute to a £10.7 million near-patient biomanufacturing facility based at the Birmingham Health Innovation Campus. This model of “near-patient manufacturing” allows advanced treatments to be developed and produced in close proximity to where patients are receiving care dramatically reducing delays between discovery and delivery.

The new University of Birmingham-led facility will work in close partnership with University Hospitals Birmingham NHS Foundation Trust, one of the UK’s leading NHS trusts, creating a fully integrated ecosystem linking research, manufacturing and frontline clinical care.

Whilst the West Midlands hosts more than 50% of the UK’s clinical trials for advanced therapies, it lacks dedicated GMP manufacturing facilities. As a result, UK-funded companies often outsource production overseas, which can delay access to treatment and limit opportunities for patients to participate in cutting-edge trials.

This investment from our government addresses that gap ensuring that therapies developed at the University of Birmingham and across the UK can also be manufactured here, improving speed, resilience and patient access.

The new facilities will also strengthen the UK’s ability to respond rapidly to future health emergencies, including pandemics, by expanding domestic manufacturing capacity for vaccines and advanced therapeutics.

The impact of this investment is already clear in pioneering work led by the University of Birmingham, including Europe’s first clinical trial of a personalised mRNA vaccine for pancreatic cancer one of the most aggressive and difficult-to-treat forms of cancer.

The investment is also expected to deliver significant economic benefits, creating highly skilled jobs, attracting global pharmaceutical and biotechnology companies to the region, and reinforcing Birmingham’s position at the centre of the UK’s life sciences sector.

Preet Kaur Gill MP said:

“This is a major step forward for Birmingham and for patients across our region.

The West Midlands is already leading the way in advanced clinical trials, but for too long we have lacked the facilities to manufacture these treatments here at home. That has meant delays, missed opportunities, and too many patients unable to access the very latest therapies.

This investment centred at the University of Birmingham changes that. By bringing together world-class research at the University with clinical excellence at University Hospitals Birmingham, we are creating a system where cutting-edge treatments can be developed, produced and delivered all in one place.

For patients including those facing devastating diagnoses like pancreatic cancer this could mean faster access to personalised, life-saving care, delivered at the point when it can make the greatest difference.

It also strengthens our NHS, builds resilience for future health emergencies, and ensures that the UK is not reliant on overseas manufacturing for critical medicines.

This is a vote of confidence in Birmingham creating highly skilled jobs, supporting supply chains, attracting investment, and cementing our region’s position as a national leader in life sciences.”

Al Carns, MP for Selly Oak commented:

“It is fantastic to see the Precision Health Technologies Accelerator (PHTA) in the heart of the Birmingham Selly Oak constituency receiving critical investment from the government's Life Sciences Innovative Manufacturing Fund. 

This investment will contribute to the fit-out of a brand-new £10.7m, 5,000 sq ft cleanroom facility where medicines, Advanced Therapy Medicinal Products and vaccines will be manufactured for both patient treatment and clinical trials.

The facility will house three cleanrooms and will strengthen the UK’s ability to develop and trial new medicines and vaccines, as well as respond more quickly to future health emergencies, while further cementing Birmingham and the West Midlands as a leading hub for life sciences and health innovation.”